Apellis Pharmaceuticals, Inc. $APLS Shares Sold by Savant Capital LLC

Savant Capital LLC decreased its stake in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) by 50.7% during the 3rd quarter, HoldingsChannel reports. The firm owned 48,886 shares of the company’s stock after selling 50,297 shares during the period. Savant Capital LLC’s holdings in Apellis Pharmaceuticals were worth $1,106,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. PNC Financial Services Group Inc. lifted its holdings in shares of Apellis Pharmaceuticals by 0.8% in the second quarter. PNC Financial Services Group Inc. now owns 58,856 shares of the company’s stock valued at $1,019,000 after purchasing an additional 465 shares in the last quarter. Amalgamated Bank grew its holdings in shares of Apellis Pharmaceuticals by 6.9% during the third quarter. Amalgamated Bank now owns 8,674 shares of the company’s stock valued at $196,000 after buying an additional 563 shares in the last quarter. Bank of Montreal Can raised its position in Apellis Pharmaceuticals by 0.7% during the second quarter. Bank of Montreal Can now owns 159,613 shares of the company’s stock valued at $2,763,000 after buying an additional 1,040 shares during the period. Treasurer of the State of North Carolina lifted its stake in Apellis Pharmaceuticals by 2.8% in the 2nd quarter. Treasurer of the State of North Carolina now owns 50,358 shares of the company’s stock worth $872,000 after acquiring an additional 1,353 shares in the last quarter. Finally, Jones Financial Companies Lllp lifted its stake in Apellis Pharmaceuticals by 206.8% in the 3rd quarter. Jones Financial Companies Lllp now owns 2,037 shares of the company’s stock worth $46,000 after acquiring an additional 1,373 shares in the last quarter. Institutional investors and hedge funds own 96.29% of the company’s stock.

Analyst Ratings Changes

APLS has been the topic of several research analyst reports. Stifel Nicolaus lowered their target price on Apellis Pharmaceuticals from $55.00 to $48.00 and set a “buy” rating on the stock in a research note on Friday, December 19th. Cantor Fitzgerald decreased their price target on shares of Apellis Pharmaceuticals from $39.00 to $35.00 and set an “overweight” rating for the company in a report on Tuesday, January 13th. HC Wainwright lowered their price objective on shares of Apellis Pharmaceuticals from $57.00 to $45.00 and set a “buy” rating on the stock in a research report on Friday, October 31st. Robert W. Baird upped their price objective on shares of Apellis Pharmaceuticals from $50.00 to $52.00 and gave the company an “outperform” rating in a research note on Friday, October 31st. Finally, Needham & Company LLC decreased their target price on shares of Apellis Pharmaceuticals from $29.00 to $28.00 and set a “buy” rating for the company in a research note on Tuesday, January 13th. Twelve analysts have rated the stock with a Buy rating, seven have given a Hold rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Hold” and an average target price of $33.00.

Insider Transactions at Apellis Pharmaceuticals

In other news, CAO James George Chopas sold 2,064 shares of the stock in a transaction on Thursday, January 22nd. The shares were sold at an average price of $21.77, for a total transaction of $44,933.28. Following the transaction, the chief accounting officer owned 49,805 shares in the company, valued at $1,084,254.85. This represents a 3.98% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Pascal Deschatelets sold 5,928 shares of the firm’s stock in a transaction on Thursday, January 22nd. The shares were sold at an average price of $21.77, for a total transaction of $129,052.56. Following the transaction, the insider owned 1,151,382 shares in the company, valued at $25,065,586.14. This represents a 0.51% decrease in their position. The SEC filing for this sale provides additional information. Over the last three months, insiders sold 125,169 shares of company stock valued at $2,700,681. Insiders own 6.80% of the company’s stock.

Apellis Pharmaceuticals Trading Down 1.1%

Shares of NASDAQ APLS opened at $22.58 on Wednesday. The business has a 50 day simple moving average of $23.57 and a 200 day simple moving average of $23.86. Apellis Pharmaceuticals, Inc. has a 52 week low of $16.10 and a 52 week high of $30.48. The stock has a market cap of $2.86 billion, a price-to-earnings ratio of 72.84 and a beta of 0.26. The company has a debt-to-equity ratio of 0.90, a quick ratio of 3.10 and a current ratio of 3.54.

Apellis Pharmaceuticals Company Profile

Apellis Pharmaceuticals, Inc, traded as NASDAQ:APLS, is a clinical-stage biopharmaceutical company focused on the development of novel therapies targeting the complement cascade for the treatment of rare and debilitating diseases. The company’s research and development efforts center on modulating complement proteins to address a range of ophthalmologic, hematologic and renal conditions. Apellis leverages its proprietary compstatin technology platform to design targeted inhibitors intended to improve patient outcomes and quality of life.

The company’s lead marketed product, Syfovre (pegcetacoplan), is an intravitreal complement C3 inhibitor approved for geographic atrophy secondary to age-related macular degeneration, with ongoing investigations in other retinal disorders.